Epstein Secrets

the presence or absence of malignant disease. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics) PSA, FREE 0.33 Not Estab. ng/mL I 0.31 10/27/201S BioReference Laboratories, Inc. Elmwood Park, NJ 07407 James Weisberger M.D. Page 3 of S Laboratory Director Prin

.2 10/27/2015 Iron 75 45-160 ug/dL 57 10/27/2015 Bilirubin, Total 0.5 <1.2 mg/dL 0.5 10/27/2015 LD 171 135-225 U/L 177 10/27/2015 Alk Phos 43 40-156 U/L 62 10/27/2015 AST 29 <40 U/L 23 10/27/2015 PHOSPHORUS 3.4 2.7-4.5 mg/dL 3.3 10/27/2015 ALT 29 <41 U/L 25 10/27/2

th different assay methods or kits cannot be interchangeably. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics). Not Estab. ng/mL to moderate or marked of the obtained used I 0.33 ¶01/27/2016 % FREE PSA TNP FREE PSA RISK ASSESSMENT The probability of prostate

5 01/27/2016 Iron 96 45-168 ug/dL 75 01/27/2016 8111rubin, Total 0.6 <1.2 mg/dL 0.5 01/27/2016 LID 206 135-225 U/L 171 01/27/2016 Alk Phos 70 40-156 U/L 43 01/27/2016 AST 32 <40 U/L 29 01/57/2016 Phosphorus 3.8 2.7.4.5 mg/dL 3.4 01/27/2016 ALT 42 HI <41 U/L 29 01/2

th different assay methods or kits cannot be interchangeably. ASSAY INFORMATION: Method Electrocheedluninescence Immunoassay (Roche Diagnostics). Not Estab. ng/mi. to moderate or marked of the obtained used 1 0.33 101/27/2016 % FREE PSA TNP FREE PSA RISK ASSESSMENT The probability of prostate

.5 01/27/2016 Iron 96 45-160 ug/dL 75 01/27/2016 8111rubin, Total 0.6 <1.2 mg/dL 0.5 81/27/2818 LD 206 135-225 U/L 171 01/27/2016 Alk Phos 79 40-156 U/L 43 01/27/2016 13T 32 <40 U/L 29 01/27/2016 Phosphorus 3.8 2.7.4.5 mg/dL 3.4 01/27/2016 ALT 42 HI <41 U/L 29 81/2